Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations

HIV Medicine

Volumn 11, Issue 7, 2010, Pages 432-438

  Bansi, L ^a   Sabin, C ^a   Delpech, V ^b   Hill, T ^a   Fisher, M ^c   Walsh, J ^d   Chadborn, T ^b   Easterbrook, P ^e   Gilson, R ^a   Johnson, M ^f   Porter, K ^g   Anderson, J ^h   Gompels, M ⁱ   Leen, C ^j   Ainsworth, J ^k   Orkin, C ^l   Nelson, M ^m   Rice, B ^b   Phillips, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UK   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g MEDICAL RESEARCH COUNCIL   (United Kingdom)

^h HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ NORTH BRISTOL NHS TRUST   (United Kingdom)

^j NHS LOTHIAN   (United Kingdom)

^k NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^l BARTS HEALTH NHS TRUST   (United Kingdom)

^m CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Antiretroviral therapy; Model; Synthesis; Time trends; UK collaborative HIV cohort (CHIC) study

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOCHASTIC MODEL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; VIRUS LOAD;

AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FORECASTING; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); STOCHASTIC PROCESSES; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 77955145227     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00809.x     Document Type: Article

References (30)

1. Mocroft A, Vella S, Benfield T. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA study group. Lancet 1998, 352:1725-1730.
2. Egger M, Hirschel B, Francioli P. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
3. Palella F, Delaney K, Moorman A. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998, 338:853-860.
4. Lampe F, Smith C, Madge S. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007, 167:692-700.
5. Sabin C, Hill T, Lampe F. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005, 330:695.
6. Mocroft A, Katlama C, Johnson A. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000, 356:291-296.
7. Jimenez-Nacher I, Garcia B, Barreiro P. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 2008, 62((4)):816-822.
8. Lohse N, Obel N, Kronborg G. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS 2005, 19:815-822.
9. Mocroft A, Ledergerber B, Viard J. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 2004, 190:1947-1956.
10. Lazzarin A, Clotet B, Cooper D. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003, 348:2186-2195.
11. Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 2008, 57:1-10.
12. Waters L, Nelson M. New drugs. HIV Med 2005, 6:225-231.
13. Fenton C, Perry C. Darunavir: in the treatment of HIV-1 infection. Drugs 2007, 67:2791-2801.
14. Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 2008, 6:427-433.
15. Phillips A, Sabin C, Pillay D, Lundgren J. HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med 2007, 8:536-546.
16. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK collaborative HIV cohort (UK CHIC) study. HIV Med 2004, 5:115-124. UK CHIC SC.
17. 2009, http://www.hpa.org.uk/webw/HPAweb&Page&HPAwebAutoListDate/Page/1201094588844?p=1201094588844, SOPHID., Available at
18. Phillips A, Pillay D, Miners A, Bennett D, Gilks C, Lundgren J. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008, 371:1443-1451.
19. Mocroft A, Horban A, Clotet B. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV Med 2008, 9:41-46.
20. Ledergerber B, Egger M, Opravil M. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
21. Staszewski S, Miller V, Sabin C. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999, 13:367-373.
22. Phillips A, Pradier C, Lazzarin A. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001, 15:2385-2395.
23. Lohse N, Jorgensen L, Kronborg G. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure. Antivir Ther 2007, 12:909-917.
24. Ledergerber B, Lundgren J, Walker S. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004, 364:51-62.
25. Quinn T, Wawer M, Sewankambo N. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921-929.
26. Bhaskaran K, Hamouda O, Sannes M. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300:51-59.
27. Hooshyar D, Hanson D, Wolfe M, Selik R, Buskin S, McNaghten A. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS 2007, 21:2093-2100.
28. Chadborn T, Delpech V, Sabin C, Sinka K, Evans B. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006, 20:2371-2379.
29. Lucas S, Curtis H, Johnson M. National review of deaths among HIV-infected adults. Clin Med 2008, 8:250-252.
30. Goubar A, Ades A, De Angelis D. Estimates of human immunodeficiency virus prevalence and proportion diagnosed based on Bayesian multiparameter synthesis of surveillance data. J R Statist Soc 2008, 171:541-580.